Petros Pharmaceuticals signs manufacturing agreement with Thermo Fisher's Patheon for Stendra

Petros Pharmaceuticals, Inc.

Metuchen (Petros subsidiary) and Patheon (Thermo Fisher) will collaborate on tech transfer and validation to manufacture Stendra at Patheon's Cincinnati facility.
Agreement covers pharmaceutical development and technology transfer services to establish and validate Patheon's ability to supply Stendra.
Commercial sale of product produced during the agreement requires a subsequent commercial manufacturing services agreement.
After successful validation, parties will execute a commercial manufacturing agreement for release of commercially saleable products.
Agreement effective until services completed; each party may terminate under customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.